First Tracks Biotherapeutics (TRAX) — Financial Flexibility Index
First Tracks Biotherapeutics (TRAX) has a Financial Flexibility Index of -2.22x as of June 2026. Free cash flow of $-31.89 Million (operating CF $-31.92 Million minus capex $25.00K) represents -2% of total liabilities ($14.34 Million). Check First Tracks Biotherapeutics (TRAX) tangible net worth to evaluate the tangible quality of the company's equity base.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
First Tracks Biotherapeutics Financial Flexibility Index (2023–2025)
Historical Financial Flexibility Index trend for First Tracks Biotherapeutics across 3 annual periods. For the full cash flow conversion analysis, see TRAX cash flow conversion.
Annual Financial Flexibility Index for First Tracks Biotherapeutics (2023–2025)
Year-by-year free cash flow to debt coverage for First Tracks Biotherapeutics. Explore TRAX cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -3.32x | $-142.84 Million | $-142.93 Million | $43.05 Million | ▼ -33.0% |
| 2024 | -2.49x | $-125.45 Million | $-125.81 Million | $50.30 Million | ▲ +7.3% |
| 2023 | -2.69x | $-92.20 Million | $-93.00 Million | $34.26 Million | — |